Anthony Altig - Assembly Biosciences Insider

Assembly Biosciences Inc -- USA Stock  

USD 30.38  0.86  2.75%

Independent Director

Mr. Anthony E. Altig is Independent Director of ASSEMBLY BIOSCIENCES, Inc., since January 2012. Since 2008, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporationrationration, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporationrationration, a publicly traded eyecare technology company, and served as a director of Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013.
Age: 60  Director Since 2012      
646 706-5208  www.ventrusbio.com

Management Efficiency

The company has return on total asset (ROA) of (26.59) % which means that it has lost $26.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.48) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Trent DavisVBI Vaccines Inc
2014
Scott RequadtVBI Vaccines Inc
2015
Robert TothDel Mar Pharmaceuticals Inc
2013
Arlene MorrisDimension Therapeutics Inc
2015
Ruth AlonVascular Biogenics Ltd
2010
Robert RosenNantKwest Inc
N/A
Dennis BrownDel Mar Pharmaceuticals Inc
2013
Steven GilmanVericel Corporation
2015
Jecheskiel GonczarowskiVascular Biogenics Ltd
2001
Michael DybbsDimension Therapeutics Inc
2015
Adam LogalVBI Vaccines Inc
2015
Ruth ArnonVascular Biogenics Ltd
2007
John BellDel Mar Pharmaceuticals Inc
2013
George MigauskyDimension Therapeutics Inc
2015
Alan RubinoVericel Corporation
2005
Lynda CranstonDel Mar Pharmaceuticals Inc
2015
John PottsNantKwest Inc
2014
Alan ColowickDimension Therapeutics Inc
2015
Dmitry GenkinVBI Vaccines Inc
2015
Dan GelvanVascular Biogenics Ltd
2005
Henry JiNantKwest Inc
N/A

Entity Summary

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and to restore health to a dysbiotic microbiome in the United States. Assembly Biosciences Inc (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 65 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Idea Optimizer Now
   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  Next  Launch Idea Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Assembly Biosciences Inc to your portfolio

Top Management

Assembly Biosciences Inc Leadership Team
Adam Zlotnick, Founder
Uri Lopatin, President, Ph.D
Myron Holubiak, Director
Lee Arnold, Executive, Ph.D
Anthony Altig, Director
Richard Colonno, Executive
William Ringo, Chairman, MBA
Richard DiMarchi, Director, Ph.D
Miguel Barbosa, Executive, Ph.D
Mark Auerbach, Director
Derek Small, CEO
Alan Lewis, Director, Ph.D
David Barrett, COO

Stock Performance

Assembly Biosciences Performance Indicators